{"disease":{"id":"relapsed-refractory-b-cell-malignancies","name":"relapsed refractory b cell malignancies"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02825836","title":"Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":130,"lead_sponsor_name":"Telios Pharma, Inc.","has_results":false},{"nct_id":"NCT03932331","title":"Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":105,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT07493174","title":"Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":86,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT04865458","title":"A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Sunshine Lake Pharma Co., Ltd.","has_results":false},{"nct_id":"NCT05780034","title":"A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Accutar Biotechnology Inc","has_results":false},{"nct_id":"NCT04689308","title":"This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":57,"lead_sponsor_name":"Minghui Pharmaceutical (Shanghai) LTD","has_results":false},{"nct_id":"NCT07002112","title":"The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT02457559","title":"Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT07345728","title":"Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies","phase":"NA","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Donghua Zhang","has_results":false},{"nct_id":"NCT04943016","title":"CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":12,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT07309900","title":"IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT05645601","title":"CAR-NK Targeted CD19 for r/r B-cell Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":12,"lead_sponsor_name":"Affiliated Hospital to Academy of Military Medical Sciences","has_results":false},{"nct_id":"NCT05588440","title":"A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Oncternal Therapeutics, Inc","has_results":true},{"nct_id":"NCT07240974","title":"Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}